NEXT Life Sciences now has two non-hormonal male contraceptive candidates in Phase II clinical trials – a long-acting reversible option and an on-demand pill – positioning the company as one of the more active players in a space that has historically seen more hype than clinical progress.
Plan A, the company’s flagship product, is a long-acting, non-hormonal, reversible-on-demand contraceptive. Its delivery device was reported as 100% successful in early trials in Australia and Canada in 2025, and the full contraceptive system entered Phase II last October.
The company has also revealed NLS-133, a non-hormonal male contraceptive pill designed to provide 24 hours of protection for either on-demand or daily use. A Phase II trial is now underway evaluating semen levels after taking the pill.
“Since over 20 percent of women cannot tolerate hormonal birth control, in some cases with severe consequences, it’s important that couples have multiple family planning options and particularly ones without hormones,” said CEO Darlene Walley, PhD.
The broader context remains compelling: half of pregnancies worldwide are unplanned, the burden of contraception falls almost entirely on women, and research published in Andrology indicates 7 in 10 men are willing to try new contraceptive methods. Yet options for men have been limited to condoms and vasectomy for decades.
